LY 3009120
Alternative Names: DP-4978; LSN 3074753; LY-3009120; Pan-Raf Inhibitor - Deciphera/Eli LillyLatest Information Update: 19 Sep 2024
At a glance
- Originator Deciphera Pharmaceuticals
- Developer Deciphera Pharmaceuticals; Eli Lilly and Company
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto oncogene protein c raf inhibitors; Proto-oncogene protein b-raf inhibitors; Ras signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Sep 2024 Discontinued - Phase-I for Cancer (Late-stage disease, Second-line therapy or greater) in USA (PO)
- 11 Jun 2024 Deciphera Pharmaceuticals has been acquired by Ono Pharmaceutical
- 28 Dec 2018 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Second-line therapy or greater) in USA (PO, Capsule)